PReS-FINAL-2185: Prognostic markers in juvenile vs. adult-onset ankylosing spondylitis by D Jadon et al.
ORAL PRESENTATION Open Access
PReS-FINAL-2185: Prognostic markers in juvenile
vs. adult-onset ankylosing spondylitis
D Jadon1*, LP Hunt2, R Arumugam1, AV Ramanan1,2, R Sengupta1
From 20th Pediatric Rheumatology European Society (PReS) Congress
Ljubljana, Slovenia. 25-29 September 2013
Introduction
Patients experiencing ankylosing spondylitis (AS) symp-
toms ≤16 years-of-age are classified as juvenile-onset AS
(JoAS), whilst those ≥17 years-of-age adult-onset AS
(AoAS). Studies from North America, China and Turkey
suggest that JoAS and AoAS patients have differing clin-
ical characteristics and functional outcomes; although
results have been inconsistent.
Objectives
This study compared JoAS vs. AoAS with respect to clini-
cal, functional and genetic outcomes, and determined
which factors were related to prognosis, as defined either
by a poor BASFI (≥5) or by a history of AS-related surgery.
Methods
143 JoAS were compared with 413 AoAS patients
attending a secondary care rheumatology hospital.
A diagnosis of AS was made using the 1987 modified
New York criteria. The following clinical parameters
were recorded: sex; age at symptom onset (JoAS only);
age at Rheumatologist-made diagnosis; the most recent
BASFI, BASDAI, BASMI; HLA-B27 genotype status; the
occurrence at any time point of psoriasis, uveitis, enthe-
sitis, inflammatory bowel disease (IBD) or AS-related
surgery (hip, shoulder or spinal).
Two group comparisons were made with continuity-
corrected Chi-squared, unpaired Student’s t-tests and
non-parametric Mann-Whitney U-tests. Logistic regres-
sion was used to adjust for time since diagnosis.
Results
At assessment, JoAS cases were slightly younger than
AoAS cases (mean age 49.0 vs. 51.9 years; mean differ-
ence in age 2.9 years, 95% CI 0.3-5.6 years). JoAS cases
had a slightly longer mean disease duration since diag-
nosis than AoAS cases (26.0 years vs. 19.3 years).
JoAS cases were more likely to have had AS-related
surgery than AoAS (18.9% vs. 8.0%, respectively; p <
0.001; or p = 0.017 after adjustment for time from diag-
nosis), and slightly more had had concurrent IBD
(11.2% vs. 6.8%; p = 0.13).
No statistically significant difference was found
between the two groups in terms of BASFI, ten BASFI
domains, BASDAI, BASMI, sex distribution, HLA-B27
positivity, psoriasis, enthesitis, or uveitis (all cases or
HLA-B27 positive cases only).
JoAS cases with psoriasis were more likely to have a
poor BASFI (≥5.0) than those without psoriasis (55% vs.
25%; p = 0.016), and were also more likely to have had
AS-related surgery than those without psoriasis (43% vs.
15%; p = 0.006).
JoAS cases with a poorer BASFI showed a trend for
symptom onset at a younger age than those with a better
BASFI (<5.0) (mean age 12.5 vs. 13.4; p = 0.08). Similarly,
JoAS cases having had AS-related surgery showed a trend
for symptom onset at a younger age than those without
surgery (mean age 12.5 vs. 13.3; trend p = 0.18).
Conclusion
This study is the first to investigate a Northern-Eur-
opean population of Rheumatologist-diagnosed JoAS
patients, and is the largest sample of prospectively-col-
lected JoAS data published. JoAS and AoAS patients dif-
fered in terms of proceeding to AS-related surgery, and
occurrence of IBD. In JoAS, younger age at symptom
onset and occurrence of psoriasis, related to poorer
prognosis. Delayed diagnosis of JoAS didn’t correlate
with prognosis.
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